T follicular helper (Tfh) CD4+ T cell, germinal center, and antibody response dysfunction in human recurrent tonsillitis

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 5U19AI142742-03

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2019
    2024
  • Known Financial Commitments (USD)

    $0
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Shane P Crotty
  • Research Location

    United States of America
  • Lead Research Institution

    La Jolla Institute For Immunology
  • Research Priority Alignment

    N/A
  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease susceptibility

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

PROJECT SUMMARY Pre-existing T cell memory to SARS-CoV-2 is detectable in ~50% of people. We first reported this, and we have since shown that this may largely be due to crossreactive memory CD4+ T cells from common cold coronavirus (CCC) infections. While this observation has been reproduced on three continents, the big unanswered question is whether these crossreactive memory T cells (i) confer some form of protection against COVID-19 disease severity, (ii) have no impact on COVID-19 severity, or (iii) increase COVID-19 disease severity. This issue has been widely discussed in scientific, public, and political spheres, and it potentially has major ramifications for understanding the COVID-19 pandemic. The direct experiment to address this topic is a longitudinal study of uninfected individuals at risk for acquisition of SARS-CoV-2, then assessing COVID-19 disease severity in individuals who contract SARS-CoV-2 infection, stratified between individuals who did or did not have pre-existing T cell memory to SARS-CoV-2.